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Introduction   
Cardiovascular disease (CVD) is the leading cause of death worldwide and it causes 47% of 
all deaths in Europe (1). Most CVD deaths are caused by coronary heart disease (CHD), and 
CHD is the single most common cause of death in the in European Union (2). CVD consists 
of stroke, peripheral artery disease and aortic disease besides CHD. Great effort has been 
made to reduce the burden of CVD through improvements in lifestyle and medical 
intervention, and CVD mortality has fallen in many European countries during the last 
decades (2-4). CVD is, however, still among the leading causes of  premature death in Europe 
accounting for about 30% of deaths before the age of 65 years (2). There is therefore still a 
strong need for more research on CVD to allow for more effective preventive measures.  
 Atherosclerosis is the predominant cause of CVD, especially CHD (5). Atherosclerosis 
represents a continuum, multi-factorial in aetiology beginning with injury to the endothelium 
covering the inside of the arterial wall. Lipid accumulation in macrophages leads to formation 
of foam cells which in turn degenerates. This subsequently leads extracellular deposition of 
lipid-rich plaques in the artery wall (6). The lipid deposition is accompanied by pathological 
proliferation of smooth muscle cells and infiltration of macrophages and other inflammatory 
cells in the arterial wall (7). The atherosclerosis often leads to narrowing of the arterial lumen 
and eventually limitation of blood flow. In advanced stages of atherosclerosis, formation of a 
fibrous cap covering the atherosclerotic plaque forms a vulnerable barrier between the plaque 
and the blood. According to current knowledge, most acute CHD events are caused by rupture 
of plaques with relatively high lipid content and thin fibrous cap, called unstable plagues (8).   
 
 Figure 1 Stages of atherosclerosis from endothelial damage and fatty streaks (left side) to advanced 
atherosclerotic plaque with a ruptured fibrous cap and thrombus formation (right side).  
(Modified from the internet, free download Google images)  
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The burden of atherosclerotic disease was recognized to reach epidemic proportions in the 
USA and Europe after Second World war, and the search for explanations and possible 
preventive measures was initiated (9). Several risk factors have been identified, and risk 
modification has proven successful with smoking cessation and reduction of blood pressure 
and cholesterol levels. Lifestyle interventions on physical activity and diet have also proven 
effective (3).  
Risk factors and predictors  
The term risk factor was introduced by Dr. William Kannel in his groundbreaking publication 
from the Framingham Heart Study in 1961(10). The underlying concept of risk factors had, 
however, been discussed long before the introduction of the term in medical literature. The 
derivation of the word "factor" from Latin implies causality, but the term risk factor was 
initially used both for causal and non-causal risk markers preceding development of diseases 
or disease events (11). During recent decades, most scientists have reserved the term risk 
factor for risk markers that have been shown to be causal in nature. Causality can in turn be 
difficult to evaluate and firmly establish in diseases of multi-factorial aetiology such as CVD. 
CVD risk factors may act by a known biological mechanism to induce a disease, but also be a 
surrogate for under underlying and often unknown factors or mechanisms. The term 
"predictor" is used when referring to a risk marker that is associated with subsequent 
development of disease, but where causality has not been found or potential causality has not 
been elucidated.  
 In this thesis, the term "risk factor" will be confined to risk markers generally accepted 
to be causal on the background of solid scientific evidence. The term "predictor" is used for 
markers that show association with subsequent disease but where causality has not been 
established. Causality cannot be elucidated solely from epidemiological studies. One may, 
however argue that a change in risk that parallels a change in the level of a predictor indicates 
a higher probability of a causal link than point measure-associations do.  
Smoking  
Smoking is associated with increased risk of all types of CVD, and the association show a 
clear dose-response relationship with the amount of tobacco smoked without a lower limit for 
harmful effects (12-14). Smoking has been firmly established as one of the most important  
modifiable CVD risk factors. Smoking cessation is therefore undoubtedly one of the most 
important measures in prevention of CVD, but may be challenging (15, 16).  
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Blood pressure 
In the Global Burden of Disease Study in 2010, elevated resting blood pressure (BP) was 
estimated to be the leading single risk factor for death and disability adjusted life years 
worldwide (17). Overwhelming evidence exists for a firm, graded and consistent association 
between resting blood pressure levels and CVD risk (10, 18). Hypertension is defined as 
resting blood pressure >140/90 mmHg, and is probably the single most important modifiable 
CVD risk factor. There is incontrovertible evidence of beneficial effects on CVD risk when 
treating hypertensive individuals at high risk of CVD with blood pressure lowering drugs and 
lifestyle interventions (19, 20). There is also some evidence that blood pressure lowering 
treatment is beneficial for individuals with mild hypertension, and even in systolic blood 
pressure (SBP) in the high normal range (130-139/85-89 mmHg) if they are otherwise at high 
risk of CVD (20).   
 Systolic blood pressure measured during physical exercise tests,  hereafter referred to 
as exercise SBP, has been shown to be an independent predictor of  CHD and CVD mortality 
among apparently healthy individuals (21-23). The potential predictive impact of temporal 
changes in exercise SBP on CHD and CVD has not been investigated before we started the 
present study.   
Cholesterol 
An association between serum cholesterol levels and future development of CHD was first 
demonstrated in the Framingham Heart Study (10, 24), although a link between cholesterol 
and atherosclerotic disease had been proposed by Anitschkow in 1908 (25). The three major 
classes of lipoproteins, very low density (VLDL), low density lipoprotein (LDL) and high 
density (HDL) were first identified by John W. Gofman (26). He also laid the foundation for 
understanding the link between the lipoprotein classes and the risk of atherosclerosis and heart 
disease (27). There is now unequivocal evidence that LDL cholesterol levels are closely 
associated with CVD risk, and reduction of LDL cholesterol levels has become a cornerstone 
in CVD prevention due to overwhelming evidence of beneficial effects from lipid lowering 
trials (28-31).  
  HDL cholesterol levels have shown a consistent and graded inverse association with 
CHD and CVD risk (32, 33). HDL is thought to mediate its protective effects against CHD 
and CVD by improving cholesterol transport from peripheral tissues to the liver, called 
reverse cholesterol transport (34). Attempts to raise HDL cholesterol levels have so far given 
conflicting evidence with regards to net clinical benefits. The reason for this is debated, and 
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may be caused by negative side effects of drugs rather than lack of effect from increasing 
HDL levels per se (35). Increasing HDL levels or improving its function therefore continues 
to be appealing methods of potential risk modification. Physical exercise and increased 
physical fitness have been shown to be associated with a small but clinically significant 
increase in HDL cholesterol (36, 37). HDL cholesterol consists of relatively large 
heterogeneous particles, and subclasses with different anti-atherogenic properties have been 
identified. Some research on physical exercise has indicated that the relative contents of HDL 
or relative proportions of subclasses may be changed by exercise, thereby improving anti-
atherogenic properties (38-40).  
Physical fitness  
Physical fitness, often also referred to as cardiorespiratory fitness has no universally accepted 
definition, but is predominantly considered to be a measure of aerobic exercise capacity. 
Maximal oxygen uptake (VO2 max = maximum volume [V] of oxygen [O2] in mL per kg 
body weight) is considered to be the gold standard of measuring physical fitness. High levels 
of physical fitness are associated with a significant and clinically important reduction in risk 
of CHD and CVD mortality as well as all-cause mortality among apparently healthy 
individuals of both genders (41-46). High levels of physical activity and physical fitness also 
show a clear inverse association with risk of developing type 2 diabetes (47-50).  
Physical fitness has been measured among all men in the Oslo Ischemia Study using a 
standardized bicycle exercise-ECG protocol described in the methods section and in former  
papers (31, 51, 52). This method of measuring physical fitness has shown a high correlation 
with VO2 max (53).  
Type 2 Diabetes  
Patients with type 2 diabetes mellitus have about four times higher incidence of CHD than the 
general population, and a two- to four-fold increased risk of CVD events (54, 55). CVD is the 
leading cause of mortality and morbidity among patients with diabetes mellitus, and it has 
been estimated that as many as 80% of patients with type 2 diabetes will develop CVD (56, 
57). Patients with type 2 diabetes have been suggested to be at the same CVD risk as patients 
with established CVD, making these patients a target for secondary prevention. However, 
while this is debated (58, 59), evidence still points toward type 2 diabetes as a strong risk 
factor for CVD. Patients with type 2 diabetes seems to have accelerated stages of 
atherogenesis on several levels, from initial endothelial injury to advanced atherosclerotic 
lesions and thrombo-embolic events (60). The link between diabetes and atherosclerosis has, 
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however, not been fully elucidated. Diabetes is a gradually developing chronic disease of 
increasing incidence and prevalence worldwide, and will have major impact on the total 
burden of CVD (61). Identifying people at increased risk of developing diabetes mellitus early 
seems essential to implement effective preventive measures.    
Prevention of CVD 
Prevention has traditionally been divided into primary and secondary prevention making a 
distinction between individuals who are asymptomatic, and those who have experienced one 
or more disease events, respectively. The usefulness of this distinction in CVD risk estimation 
has been questioned since current knowledge indicates that atherosclerosis evolves as an 
almost continuous process from asymptomatic damage of the arterial endothelium into 
symptomatic disease of various severity (3). Nevertheless, several interventional trials have 
used the distinction, and it is often easier to implement intensive preventive measures in 
secondary prevention since it may be easier to acknowledge the need for risk reduction after 
having experienced a CVD event (3). Despite major advances in secondary prevention, 
individuals who have best secondary prophylaxis available today still have a high residual risk 
of new CVD events (11, 28, 62). Identifying new predictors and risk factors seems necessary 
in order to further improve preventive measures.  
 It is estimated that 25 to 50 % of all serious CHD events occur among individuals with 
no prior symptoms (63, 64). Primary prevention seems uncontroversial in individuals at high 
risk of future CVD. Most CVD events in a general population occur, however, among people 
who are not categorized as being in a high risk group. Identifying persons that are likely to 
benefit from preventive measures therefore continues to be a great challenge and precise risk 
estimations tools are necessary (3).   
Risk estimation  
Smoking, hypertension and total cholesterol besides age and gender are often referred to as 
classical risk factors, and are used in most risk prediction models. The most widely used are 
the Framingham and the SCORE risk charts (3, 65). The SCORE system is designed to be 
used in primary prevention, estimating the 10-year risk of fatal CVD, and has made two 
different models; one for countries with high CVD risk and one for low-risk countries (3).    
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Figure 2  SCORE risk chart for low-risk countries  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10-year risk of fatal cardiovascular disease (CVD) in countries at low CVD risk based on the following 
factors: age, sex, smoking, systolic blood pressure and total cholesterol. The risk of total (fatal + non-fatal) 
CVD events will be approximately three times higher than the figures given. (Adapted from the European 
Guidelines on cardiovascular disease prevention in clinical practice version 2012)  
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 Risk charts have been widely applied in risk estimation, but their positive- and 
negative predictive value has been questioned. The positive predictive value of risk scoring 
systems is highly dependent of the local CVD prevalence and population characteristics, e.g 
the higher prevalence the better positive predictive value (66). Beside local adaptation of risk 
stratification models, attempts have been made to add other risk markers to improve the 
predictive value. Significant improvements have proven more difficult to achieve than 
expected (3). HDL cholesterol has been one of few predictors that has proven to improve risk 
estimation in all risk groups, and has therefore now been implemented in the electronic 
version (http://heartscore.org) of the SCORE risk system (3, 67). Besides HDL, physical 
fitness and other exercise predictors including exercise SBP have also shown to be possible 
candidates for improving risk estimation (42, 68, 69).  
Background for the present study 
The Oslo Ischemia Study was initiated in 1971 at Rikshospitalet with the primary aim to 
search for possible, significant coronary artery disease among apparently healthy, middle-
aged men. Since the study start in 1972, the Oslo Ischemia Study has provided significant 
contributions to the knowledge of CHD epidemiology. Physical fitness was for the first time 
shown to be an independent, long-term predictor of CVD mortality and all-cause mortality 
among healthy middle-aged men in the Oslo Ischemia Study (44). Most studies conducted in 
the cohort have provided valuable knowledge about exercise-ECG test findings and CHD (22, 
23, 42, 43, 51, 52, 70-77). Findings from the Oslo Ischemia Study cohort have also 
contributed to the knowledge about maternal heritage in diabetes and the association between 
fasting blood glucose and CVD mortality (78, 79).  
 In most epidemiological studies to date, point measures of potential predictors and risk 
factor have been performed and study participants have thereafter been followed for a certain 
time. The uncommon availability of repeated surveys with clinical examinations, blood tests, 
ECG and bicycle exercise-ECG tests in the Oslo Ischemia Study represents an opportunity to 
study the impact of both point measures of-, and temporal changes in predictors of CVD and 
diabetes.  
 When identifying several predictors or risk factors, it may be challenging to estimate 
the independent effect of each factor on the outcome. The effect of one factor may be 
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dependent upon the level of another factor, and the effect of the two on the outcome is not 
additive. This is called interaction, and has been considered since the "early era" of risk factor 
research although the effect of single risk factor or predictors has received most attention (10, 
24, 80). The Oslo Ischemia Study also contains data suitable to study interactions between 
predictors.  On this background, we aimed to study interactions between markers in prediction 
of CVD and diabetes in the present study. Furthermore, we aimed to utilize the opportunity to 
investigate effects of temporal changes in predictors. Predictors that may improve CVD and 
diabetes risk estimation attained our interest.  
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Aims  
 
1. There is firm evidence that the HDL cholesterol is inversely associated with risk of 
future CHD, and also substantial evidence that the level of physical fitness and 
physical activity may influence the HDL level. Some evidence indicates that the 
structure and function of HDL may be more favourable with increased physical 
activity and fitness.  
 We therefore aimed to study: If the predictive ability of HDL for CHD 
(including angina pectoris, non-fatal myocardial infarction and CHD death) is 
dependent upon physical fitness and changes in physical fitness. Further, if physical 
fitness influences the predictive ability of HDL for CHD death, CVD death and all-
cause death.  
 
2. Increasing evidence indicates that SBP measured at low- or moderate exercise 
intensity may be even more closely associated with future risk of CVD death than 
resting SBP. The prognostic impact of temporal changes in exercise SBP has, 
however, not been studied before.  
 We therefore aimed to study if seven-year changes in SBP measured at 100W 
workload predict CHD and mortality, and if these possible associations are influenced 
by physical fitness and changes in physical fitness.  
 
3. Elevated fasting serum triglycerides (FTG) have been associated with diabetes risk. 
Whether physical fitness modifies the FTG-diabetes association remains, however 
elusive. Physical fitness also reflects important elements of lifestyle and is inversely 
associated with diabetes risk.  
 We aimed to study whether the possible association between FTG and long-
term risk of diabetes is modified by the level of physical fitness and temporal changes 
in physical fitness. Additionally; we studied if temporal changes in FTG levels predict 
future diabetes risk.   
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Material and methods   
Subjects  
All subjects in the studies of the present thesis constitute sub sets of men included in The Oslo 
Ischemia Study in the years 1972-75. The Oslo Ischemia Study was initiated in 1971 by Jan 
Erikssen (JE) who worked at Rikshospitalet at the time. Jan Erikssen was the primary 
investigator, designed the study and conducted the inclusion and the first and second survey. 
In subsequent surveys, Erikssen has cooperated with other clinicians and PhD students, but he 
has kept the overview over all examinations, data gathering and taken an active part in all 
publications. Originally, the main aim of the Oslo Ischemia Study was to examine apparently 
healthy men with bicycle exercise test, uncover subclinical coronary artery disease and 
thereby be able to estimate the prevalence and incidence of coronary artery disease among 
apparently healthy middle-aged men. Time of follow-up was initially planned to be 
approximately 5 years, but the men have been followed up to 35 years. Four clinical surveys, 
one postal questionnaire-survey and two nationwide searches of hospital records have been 
performed during the 35 years (Figure 3, flow chart).  
 
 Figure 3 Oslo Ischemia Study flow-chart showing all surveys during up to 35 years follow-up   
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Selection and Inclusion  
All men aged 40-60 years who were apparently healthy according to available health files and 
worked full time in five companies based in the Oslo region (Custom Services, Norwegian 
Railways, Postal Services, Siemens Inc. and Telecommunication Services) were invited to 
participate in the study. The above mentioned companies were selected because of their size 
in addition to having a company health department providing annual or biannual routine 
examination for the employees for at least the previous five years. All health records of the 
companies were scrutinized by Jan Erikssen in collaboration with the companies` chief 
physician during last half of 1971 and first half of 1972. Only men who were labelled 
"apparently healthy" according to predefined criteria were found eligible and invited to 
participate in the study. Criteria for being apparently healthy were the following: The men 
should be free from known or suspected heart disease, cancer, diabetes, severe lung, liver or 
renal disease, drug treated hypertension and any chronic drug regimen. Further, men who 
were judged unable to conduct a symptom-limited bicycle exercise test for muscular, 
orthopaedic or neurological reasons were not labelled apparently healthy.  All 2341 men who 
fulfilled the inclusion criteria were invited to participate, and 2014 men (86%) gave their 
consent.  
Clinical Surveys   
All participants were given an extensive health questionnaire one week prior to Survey 1, 
administered through the respective health departments of their companies. The questionnaire 
was made in Norwegian specifically for the Oslo Ischemia Study, and included a Norwegian 
translation of the WHO angina-, the WHO claudicatio-, and the MRC respiratory 
questionnaire.  A brief description of relevant questions is given in the publications when 
relevant. All questionnaires were reviewed together with all the participants by the primary 
investigator (JE) during the examination day to ensure that all questions were understood and 
answered correctly.  
 Survey 1 was conducted from August 1972 to March 1975 after having conducted a 
pilot study of 80 men from the community. The pilot study was performed partly in order to 
determine the level of the first workload on the exercise test. All men were asked to fast for at 
least 12 hours and abstain from smoking for at least 8 hours prior to examination starting at 
07.00 AM. The study protocol generally followed the standardized principles described by 
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Rose and Blackburn in their WHO-publication of 1968: Cardiovascular Surveys and Methods 
(81). Clinical examinations and test were performed in the order as shown in Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Details of the clinical examinations, blood tests and other test have been described in previous 
publications and in the publications in this thesis when relevant for the particular study. No 
independent method paper has been published from the Oslo Ischemia study.   
Subsequent clinical surveys (as depicted in Figure 3) were virtually identical to Survey 1 with 
minor deviations. Deviations between surveys have been described in the publications when 
relevant.  
Resting blood pressure measurements 
Blood pressure measurements were performed under standardized conditions after the 
subjects had been familiarized with the laboratory and after 5 minutes supine rest in a quiet 
room. Measurements were repeated 3 times for all subjects using a mercury 
sphygmomanometer and auscultator method. Further details about blood pressure 
measurements have been described in previous publications (74, 82-84).  
Blood tests  
All blood samples were obtained in a fasting state, before exercise test was performed in all 
participants. Blood tests were analysed by standard methods of the time of analysis.  Further 
details about tests and variation coefficients are provided in publications when relevant.  
Figure 4 Order of examinations (from top left). BP: blood pressure, HR: heart rate    
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Bicycle exercise ECG test and physical fitness 
All men performed a standardized bicycle exercise ECG-test at the clinical examinations. The 
initial workload was 6 minutes on 100W for 98 % of the men. The other 2% of the men 
started with 50W at Survey1. The workload was increased by 50W every 6 minutes and the 
men were encouraged to continue exercise until exhaustion or until exhibiting signs or 
symptoms causing an early test termination. SBP was measured to the nearest 5 mmHg every 
second minute throughout the test. Physical fitness was defined as the total bicycle exercise 
work (Joule), calculated as the sum of work at all workloads, divided by body weight (kg). 
Details about the exercise test have been described in present papers and previous 
publications (44, 51, 52, 70).   
Endpoints and follow-up 
Endpoints in the Oslo Ischemia Study have been identified by the postal questionnaire in 
1987, the nationwide searches of hospital records in all Norwegian hospitals in 1995-96 and 
2005-07 besides cases history and questionnaires at the clinical surveys, survey 1-4 (Figure 
3). Only the last follow-up, survey 6, will be described in detail in this section.  
Survey 6  
Survey 6 was conducted during the years 2005-07 by MD Johan Bodegard with permission 
from Norwegian Data Inspectorate and the Norwegian Board of Health. The survey was 
performed as a search in all hospital records for all participants of the Oslo Ischemia Study in 
all Norwegian hospitals. Hospital records were manually assessed. All records found 
regarding admissions, outpatient notes and referral letters, both in paper- and electronic 
versions, were used and the following data were registered: 
1. Name and date of birth with social security number 
2. Date of admission and discharge, number of days they were admitted and name of                                
the hospital 
3. Up to three diagnoses for each admission (ICD-10)  
4. Separate registration of the following diseases and the year they occurred; 
 Unstable angina pectoris 
 Myocardial infarction with localization (anterior wall, inferior wall etc)  
 Myocardial infarction without symptoms 
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 Percutaneous coronary intervention (PCI)  
 Coronary artery bypass surgery (CABG)  
 Aortic valve replacement (AVR) 
 Intermittent claudication  
 Surgery for claudication  
 Transitory ischemic attack  
 Stroke (ischemic and haemorrhagic) 
 Hypertension  
 Diabetes mellitus  
 Atrial fibrillation  
 Chronic obstructive lung disease (COPD)  
 Cancer, categorised  
5. Date of death with category of diagnosis (coronary heart disease, cardiovascular 
disease, infection, cancer, joint and connective tissue diseases, poisoning, trauma and 
suicide)  
6. Whether the patient died in a hospital and if  autopsy was performed. Results of 
autopsy was registered. 
7. Important remarks.   
 Complete updates of cause-specific deaths were obtained from Statistics Norway until 
2008. Statistics Norway has record of cause of death in all Norwegians who have died with a 
delay in completeness of 6 months. 
 Morbidity and mortality data are complete up to December 31st, 2007, and none was 
lost to follow-up.  
 Combined endpoints have been used in Paper 1 and 2. These endpoints are defined in 
the respective papers.  
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Statistical analyses  
Statistical analyses were mainly performed using the JMP® 9 statistical software (SAS 
Institute Inc., Cary, NC, USA). Some additional analyses were performed using the SAS® 
version 9.2 (SAS Institute Inc., Cary, NC, USA). A data analysis plan was made for the main 
hypotheses and aims before statistical analyses were performed. Additional analyses specific 
for each study were performed to answer new hypotheses emerging during our work, or as 
requested by reviewers.  
 Kendall`s rank test was used to assess correlation (trend) between subgroups (i.e. 
tertiles, quartiles or other specified categories) of participants and baseline- or examination 
characteristics. Differences in data between groups were tested by Student’s t-test or 
Pearson’s chi-square test according to data type. A two-tailed p value < 0.05 was considered 
statistically significant.  
 Survival was analysed using Kaplan Meier plots and tested with log rank tests. Cox 
proportional hazard regression used for all endpoints examined to calculate hazard ratios and 
testing statistical significance in prediction.  
The distribution of all variables used in survival analyses was checked, and variables with a 
skewed distribution were logarithmically transformed before entered into survival analyses.  
Significant variables in univariate analyses (p<0.05) were entered into multivariate analyses 
and prediction models were mainly indentified by stepwise backward elimination.  
 In paper 3, the Directed Acyclic Graph (DAG) approach was used (85). The DAG 
method is designed to provide suitable models for assessing the causal effect of one variable 
upon another. Given a list of potential causal relations between the total available set of 
variables, the DAG approach selects a set of variables to be included in the model that 
minimize bias by retaining in the model potentially confounders while eliminating 
intermediate variables.  
 Interactions between predictors were analysed by entering the cross product of the two 
predictors studied for potential interaction into the Cox analyses in addition to the other 
variables in the final prediction model. We also stratified men according to age-adjusted 
physical fitness and made separate Cox analyses in for the different strata.   
 Specific details about statistical analyses are given in the respective papers when 
relevant.    
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Summary of results   
 
Paper 1 HDL, Physical fitness and coronary heart disease 
In this paper, we tested the hypothesis that physical fitness influences the long-term 
prognostic impact of HDL for risk of CHD (main combined endpoint consisting of angina 
pectoris, non-fatal myocardial infarction and CHD death) and secondly death from CHD, 
CVD and all-cause when adjusting for classical CVD risk factors. Thirdly, we studied the 
possible interaction between physical fitness and HDL in CHD risk prediction and finally the 
possible influence of changes in physical fitness on the HDL-CHD risk association. This 
study included 1357 men who were apparently healthy and had HDL measured at Survey 2.   
 Mean HDL was 1.55 mmol/l (range 0.81-3.33 mmol/l) and follow-up from baseline 
until death or end of observation was 20.8 years (range 0.3-28.0 years). The highest (Q4) and 
the second highest (Q3) HDL quartiles were associated with lower risk of CHD, and 
adjustments for physical fitness had minor impact only on the results (Table 1).   
 Q4 was also associated with lower risk of CHD death (HR: 0.54, CI: 0.35 to 0.83), 
CVD death (HR: 0.63, CI: 0.45 to 0.87) and all-cause death (HR: 0.80, CI: 0.65 to 0.99) 
compared to Q1 when multiple adjusted (age, smoking status, SBP and total cholesterol) 
without physical fitness. Adjustments for physical fitness imposed minor changes only to the 
risk association between HDL and death from CHD and CVD, while all-cause death fell short 
of statistical significance. Q3 was associated with lower risk of death from CHD and CVD 
compared to Q1 when age-adjusted, but only with lower risk of CVD death when multiple 
adjusted (detailed data shown in paper, Table 1).   
 We found no interaction between HDL and physical fitness. The influence of changes 
in physical fitness over 8.6 years on the prognostic impact of HDL for CHD was studied in a 
sub population of 919 men free from CHD and cancer at Survey 3. Changes in physical 
fitness over 8.6 years had minor impact on the association.  
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Q1 
(0.81-1.30 mmol/l) 
n = 348 
Q2 
 (1.31-1.51 mmol/l) 
n = 325 
Q3  
(1.52-1.71 mmol/l) 
n = 344 
Q4 
 (1.72-3.30 mmol/l) 
n = 340 
CHD, n (%) 144 (41.4) 113 (34.8) 90 (26.1) 92 (26.1) 
Age-adjusted 1.00 0.78 (0.61-1.00) 0.55 (0.42-0.72) 0.57 (0.44-0.74) 
Multiple adjusted* without PF  1.00 0.80 (0.62-1.02) 0.58 (0.44-0.75) 0.57 (0.44-0.74) 
Multiple-adjusted* with  PF 1.00 0.83 (0.64-1.06) 0.60 (0.46-0.79) 0.61 (0.47-0.80) 
Table 1 Risks of CHD among men in HDL cholesterol quartiles (Q1-Q4) compared to the lowest quartile (Q1) 
Risks are given in hazard ratios (95% CI), CI = 95% confidence interval, CHD = coronary heart disease 
including angina pectoris, non fatal myocardial infarction and CHD death. PF = physical fitness, n = number 
of men.  *adjusted for age, smoking status, systolic blood pressure and total cholesterol. 
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Paper 2 Changes in exercise blood pressure   
In this study, we tested the hypothesis that changes in exercise SBP during seven years predict 
CHD (including angina pectoris, non-fatal myocardial infarction and fatal coronary heart 
disease) and mortality over the following 28 years. Peak SBP at 100W workload (SBP100W) 
was measured among 1,392 men at Survey 1, and repeated at Survey 2. The men were divided 
into quartiles (Q1-Q4) of change in peak SBP100W.  
 Mean resting SBP was 127.3 mmHg and mean SBP100W was177.3 mmHg. Mean 
SBP increased by 3.4 mmHg and SBP100W with 3.0 mmHg from Survey 1 to Survey 2. Risk 
of CHD increased with increasing quartiles of seven year changes in SBP100W (Figure 5).   
 The highest quartile, Q4, was associated with 1.55-fold (95% CI; 1.17-2.03) risk of 
CHD and 1.93-fold (1.24-3.02) risk of CHD death compared to the lowest, Q1, when adjusted 
for family history of CHD, age, smoking status, resting SBP, SBP100W and total cholesterol 
at first examination (Model 1). Q4 had a 1.40-fold (1.06-1.85) risk of CHD and a 1.70-fold 
(1.08-2.68) risk of CHD death when further adjusted for physical fitness and change in 
physical fitness (Model 2). Q4 was associated with increased risk of death from CVD and all-
cause compared to Q1 in Model 1, but not in Model 2.  
 Our results indicate that an increase in SBP100W over seven years is independently 
associated with increased long-term risk of CHD, CHD death and CVD death.  
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Observation time (years)
Figure 5 Survival free from coronary heart disease according to change in exercise 
blood pressure  
Kaplan-Meier curves showing survival (%) free from coronary heart disease in quartiles (Q1-
Q4) of seven-year change in peak systolic blood pressure at exercise load of 100W among 1392 
initially healthy men.  
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Paper 3 Fasting serum triglycerides and diabetes 
In this study, we tested the impact of physical fitness on the association between fasting 
serum triglycerides (FTG) and diabetes risk, and secondly if temporal changes in FTG predict 
diabetes risk.  
 A sub population of the Oslo Ischemia study cohort of 1,962 men who had fasting 
serum triglycerides (FTG) and fasting blood glucose measured at Survey 1 were included in 
this study. Out of the 1,962, 1; 387 were still healthy at Survey 2 and reached our criteria for 
studying temporal changes in FTG and diabetes risk.  
 During 35 years follow-up 202 out of the 1962 (10.3%) men developed diabetes. 
Compared with the lowest, the upper FTG tertile had 2.58-fold (95% CI; 1.81–3.74) diabetes 
risk adjusted for age, fasting blood glucose and maternal diabetes, and 2.29-fold (95%CI; 
1.60–3.33) when also adjusting for physical fitness. Compared with unchanged (±25%) FTG 
levels (n=664), FTG reduction more than 25% (n=261) was associated with 56% lower (0.44; 
95% CI; 0.24–0.75) diabetes risk, whilst FTG increase of more than 25% (n=462) was 
associated with similar risk. These associations were unchanged when adjusting for physical 
fitness and temporal changes in physical fitness.   
 When stratifying men into those with age-adjusted physical fitness below and above 
the median at inclusion, we found a possible interaction between FTG and physical fitness on 
diabetes risk. Our results indicated a stronger association between FTG levels and diabetes 
among unfit than fit men.   
 High FTG-levels predicted long-term diabetes risk in healthy middle-aged men, and 
the association was only modestly weakened when adjusted for physical fitness. A reduction 
in FTG was associated with decreased diabetes risk.    
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Discussion of results  
HDL   
The novel finding was that physical fitness and changes in physical fitness did not change the 
prognostic impact of HDL on CHD and death from CHD and CVD.  In line with existing 
evidence, we found that HDL was a powerful long-term predictor for these endpoints (67, 86-
89). HDL appeared to be the strongest predictor of CHD compared to other classical risk 
factors including physical fitness in this study. We also found that the largest difference in 
risk of future CHD in our study was between HDL levels of 1.31-1.51 mmol/l and 1.52-1.71 
mmol/l. Men with HDL in the range 1.52-1.71 mmol/l and 1.72-3.30 mmol/l appeared to have 
similar risk, indicating that HDL increase above 1.50 mmol/l not necessarily is associated 
with further risk reduction which is in accordance with previous findings (90, 91).  
 Blood lipid response to exercise training and increases physical fitness is highly 
variable. Most studies on HDL and exercise have been small with less than 200 participants 
and of relatively short duration, although one study by Leon et al included 675 healthy 
subjects of both genders (92, 93). Results have been conflicting, but a meta-analysis by Leon 
et al. showed that the increase in HDL levels in the training groups of  20 studies without 
dietary intervention, including about 2200 subjects, was about 4.6% (range: decrease of 5.8% 
to increase if 25%) in average across studies (92). HDL cholesterol consist of complex 
particles with varying density and possibly also heterogeneous properties regarding reverse 
cholesterol transport and protection from CHD (94). HDL cholesterol consists mainly of two 
subclasses, the larger and less dense HDL2 particles and the smaller and denser HDL3 
particles. HDL2 particles have been considered to be most favourable in reverse cholesterol 
transport and to possess the most beneficial anti-atherogenic properties, although this has been 
questioned (93). Increase in HDL due to high physical activity or exercise intervention has 
mostly been ascribed to increase in HDL2 or large HDL particles.  The relative increase in 
HDL2 and HDL3 may, however, vary between individuals (40, 92, 94-97). On this 
background, it is reasonable to question if the predictive ability of HDL on CHD and CVD is 
equal along the whole spectrum of physical fitness in a population since HDL in fit and unfit 
people may have different composition. Our findings did, however, not support the hypothesis 
that the level of physical fitness modifies the predictive ability of HDL for CHD and CVD. 
 How do we explain our results, and should they be considered surprising? There are 
several reasons why we do not find our results surprising. First, the inverse association 
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between CHD and HDL levels has been consistent and of similar magnitude in several 
epidemiological studies likely to have included participants along the whole spectrum of 
physical fitness and physical activity (32, 33, 90, 98). Second, evidence of correlations 
between levels of specific HDL sub fractions and reverse cholesterol transport has been scarce 
and conflicting. Olchawa et al. compared measures of reverse cholesterol transport in 25 male 
athletes and 33 normally active men. They found increased cholesterol efflux from peripheral 
tissues to plasma among the athletes, but this could be fully accounted for by an increased 
number of HDL particles rather than an increased ability of HDL particles to promote 
cholesterol efflux (99). Third, exercise induced changes in HDL-composition and markers of 
reverse cholesterol transport have not been validated as surrogates for long-term protection 
against CHD. On the contrary, we cannot totally reject the possibility of enhancing beneficial 
properties of HDL in CHD protection from one single study.  
 The finding that physical fitness and temporal changes in physical fitness had minimal 
or no impact on the predictive ability of HDL should not be interpreted to question the 
association between increased physical fitness and increased HDL (36, 37). In line with 
existing evidence, we found a significant correlation between HDL levels and physical 
fitness. Since HDL measurements were not repeated in our study, we were not able to 
examine a possible association between temporal changes in physical fitness and HDL levels. 
Our findings, however, do not support earlier suggestions of clinically important differences 
in beneficial properties of HDL dependent upon physical fitness. We actually found the 
opposite because the predictive ability of HDL appears to be equal along the whole gradient 
of physical fitness in a population of apparently healthy men. If the structure and properties of 
HDL particles were highly dependent of the level of physical fitness, we would expect to find 
a significant interaction between HDL and physical fitness.   
Exercise blood pressure  
Our study of changes in exercise blood pressure was the first to investigate the possible 
association between temporal changes in exercise blood pressure and long-term risk of CHD 
and death. We found that seven-year change in SBP at a moderate exercise load of 100 Watt 
(SBP100W) was a significant predictor of CHD and death. The prognostic impact remained 
significant when adjusted for classical cardiovascular risk factors. Our findings indicate that 
exercise SBP adds prognostic information beyond classical risk factors on risk of CHD death 
among healthy middle-aged men.  
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 The association seem to be particularly strong for CHD death followed by death from 
CVD and all-cause (Paper 2, Table 3 and 4). Since no other study has examined the 
prognostic impact of temporal changes in exercise SBP, differences in significance levels and 
prognostic power between the various endpoints should be interpreted with caution. 
 Exercise blood pressure (BP) is a measure of several properties of the cardiovascular 
system, and it is therefore not surprising that exercise SBP shows a closer association with 
CVD death than all-cause death that also includes deaths from causes not related to 
cardiovascular function. Whether existing evidence supports differences in the associations 
between exercise SBP and various forms of CVD remain elusive. This is due to difficulties in 
comparing results obtained from studies with major differences in population selection, 
methodologies and test procedures (100).  
 Adjustments for physical fitness and seven-year change in physical fitness had a small 
but significant impact of the results, abolishing the association between all-cause death risk 
and seven-year change in SBP100W. We also found that the above mentioned associations 
concerned men with normal resting BP (<140/90 mmHg).  Our results support and extend 
existing evidence of a consistent, graded and independent association between SBP measured 
at low- to moderate exercise intensity and CVD- risk.  
 The importance of exercise SBP and an exaggerated SBP response to exercise has 
been debated, and results have often been considered conflicting. One source of conflicting 
results has been lack of consensus of BP values or magnitude of BP increase that represents 
an exaggerated BP response (101). Whether BP measured at low to moderate exercise 
intensity or at maximal intensity, eventually peak SBP during exercise test is the best 
predictor of future CVD events has also been a matter of debate (101).  
 In both the present and previous publications from the Oslo Ischemia Study, 
SBP100W has been a significant predictor of CHD and death from CHD and CVD when 
adjusted for classical CVD risk factors. Maximal SBP (almost invariably SBP measured at 
maximum workload just prior to termination of exercise) has, however not been an 
independent predictor of future CVD events (22, 23, 73). Our findings  are in line with results 
from a recent meta-analysis of 9 studies conducted by Schultz et al with data from 46,314 
individuals followed 15 years in average (101). Schultz et al. found that an exaggerated SBP 
response at moderate-, but not at maximal workload predicted CVD events when adjusted for 
age and causal BP in addition to other classical CVD risk factors. The existing evidence for a 
significant association between exercise SBP at moderate workload and future CVD risk 
appears to be robust. The added evidence from the present study show that also temporal 
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changes in exercise SBP at moderate workload may be a powerful predictor of future CHD 
and CVD. Our findings underline the need for further studies to evaluate if an exaggerated 
SBP response to exercise may be involved in the pathophysiological pathways. Further, 
antihypertensive treatment to prevent CVD in individuals demonstrating exaggerated exercise 
SBP response seems even more relevant than before. Few studies have examined potential 
treatment so far, but exercise training, weight loss and spironolactone have shown promising 
results on exercise SBP (102, 103). These studies have, however, been small (n=115 in both 
studies) and not designed to assess effects on CVD risk. In order to conduct future studies of 
high quality with comparable results, the scientists should try to reach a consensus with 
regards to definitions of normal versus exaggerated BP responses to exercise.  
 Our findings may be important since they pave the way for further research using 
exercise BP e.g. for assessing risk modification over time.   
Exercise BP at moderate versus maximal workload, mechanisms  
 One reason that exercise SBP at moderate workload seems to be closer associated with 
CVD risk than SBP at maximal workload may be that it is more difficult to obtain reliable 
measurements at high-intensity exercise because of noise and movement artefacts. In the 
meta-analysis by Schultz et al, it is also pointed out that the statistical power to detect an 
effect of maximal exercise BP was lower than for exercise BP at moderate workload due to 
small number of studies available for pooled analysis at maximal exercise workload (101). In 
the Oslo Ischemia Study cohort, there has been a consistent close association between 
exercise SBP at 100W and CHD, CHD death and CVD death in all studies and analyses. 
Further, the lack of association between maximal SBP and the same endpoints has also been 
consistent. All blood pressure measurements at Survey 1 and 2 both at rest and during 
exercise were performed by the same investigator (JE). Thus, the above mentioned limitations 
seem unlikely to explain why SBP100W is a better predictor of the two for CVD events.  
 In our study, the participants started directly at a workload of 100W. This workload 
represents a sudden and relatively demanding workload for most individuals. The sudden 
increase in cardiac output needed to meet metabolic demands causes an abrupt increase in 
blood pressure unless accompanied by reduction in peripheral resistance caused by 
vasodilatation. Reduction of peripheral resistance is in turn dependent upon arterial 
compliance, the autonomic nervous system and endothelial properties (104-106). A steep rise 
in exercise SBP, most often reflected in a high SBP at moderate workload may better reveal 
subtle impairments in vasodilatation than maximal SBP as the cardiovascular system has had 
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short time to adapt to the an increased cardiac output (21). At maximal workload,  the 
cardiovascular system has had more time to adapt to the increased cardiac output, and the 
peak SBP reached may also be influenced by CHD or impairment in left ventricular function 
(107). Although the men in the Oslo Ischemia Study cohort were apparently healthy, 
subclinical disease cannot be excluded. Even so, it is important to make a distinction between 
healthy individuals and those with known CVD as blood pressure responses to exercise may 
be different (107).   
Fasting serum triglycerides  
The present study was the first to show that fasting serum triglyceride (FTG) levels remain 
significant predictors of diabetes risk also after adjustment for physical fitness, and that 
physical fitness modifies this association only modestly, however somewhat more among 
unfit than among fit subjects. As discussed in paper 3, there are strong indications that almost 
all cases of diabetes in this study were type 2 diabetes. For the first time, we have shown that 
a reduction in FTG levels over time predicts reduced risk of type 2 diabetes among healthy 
middle-aged men. Previous evidence for an association between longitudinal changes in 
triglycerides and type 2 diabetes-risk is scarce, albeit existing for younger men (108).   
  Direct comparisons of the association between FTG and type 2 diabetes between our 
study and studies of other cohorts are inferential because of differences in baseline 
characteristics (109, 110). Tirosh et al followed 13,953 men for 10.5 years (108) with similar 
FTG levels but lower mean age at inclusion (32.4 years), which may explain the lower 
incidence of type 2 diabetes as compared to our study. Their main finding was, however, 
similar to ours with a HR of 2.01 (1.20 –4.38) for risk of diabetes in the highest FTG tertile 
(108). Similar findings have been demonstrated among women (110). Consistent with 
findings from these studies, FBG and BMI were strong predictors of diabetes in the present 
study (109, 111, 112). 
 Whether triglycerides play a causal role in the development of diabetes, or if raised 
serum triglyceride levels is a consequence of underlying abnormalities in glucose metabolism 
elucidated remains unknown. There are, however, several supporting arguments for a 
potential causal role. Hypertriglyceridemia is associated with higher plasma concentrations of 
free fatty acids, reduced insulin sensitivity and increased hepatic glucose production (40, 113-
116). Furthermore, increased free fatty acids and insulin levels stimulate hepatic esterification 
of free fatty acids to triglycerides that may in turn further increase serum triglyceride levels 
(117). Elevated serum triglyceride levels may therefore be part of a series of adverse 
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metabolic changes eventually leading to diabetes. This hypothesis is supported by studies 
reporting reductions in hepatic and pancreatic triglyceride following calorie restriction, also 
reflected in serum triglyceride levels. These findings have in turn been shown to be associated 
with improved insulin sensitivity in type 2 diabetes (118). Insulin sensitivity is associated 
with physical fitness, and may therefore explain some of the effect of physical fitness on the 
triglyceride-diabetes association (40).  
 Reduction in FTG levels of more than 25% over 7.3 years predicted significantly 
reduced risk of diabetes in the present study. Fasting serum triglyceride levels and changes in 
those over time are probably sensitive markers of lifestyle and alterations in lifestyle such as 
physical activity and eating habits (119). Our results indicate that changes in FTG are 
associated with changes in other parameters related to lifestyle such as cholesterol, BP, BMI 
and physical fitness. Changes in BMI were not associated with diabetes risk in our study, and 
did not change results. One should, however keep in mind that changes in BMI were 
numerically low among the 1392 men. The reduced risk associated with FTG reduction 
remained significant when adjusting for point measures and changes in other predictors of 
diabetes. This may indicate that factors other than lifestyle, e.g., genetics, also determine 
changes in FTG levels over time (120).  
 Even if serum triglycerides may be partly determined by genetics, our results indicate 
that is possible to influence triglyceride levels by improving physical fitness and lifestyle. 
Interventions to lower triglycerides might lower the risk of type 2 diabetes, but this has to be 
confirmed in randomised controlled trial.  
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General discussion 
We have investigated the predictive impact of HDL and exercise blood pressure on the risk of 
CHD and death, and the predictive impact of fasting serum triglycerides on diabetes. In all 
studies, we have studied the impact of physical fitness and changes in physical fitness in risk 
prediction. Relatively few epidemiological studies on healthy individuals have studied the 
impact of temporal changes in predictors and future CVD- or diabetes risk. The limited 
availability of repeated clinical examinations including exercise tests of all men in the Oslo 
Ischemia Study represents a rare opportunity to study the impact of repeated measures in risk 
prediction.   
Physical fitness and physical activity  
Physical fitness is usually defined as maximal aerobic capacity, and maximal oxygen uptake 
(V02max) is considered to be the gold standard for assessing physical fitness. Our method of 
measuring physical fitness has shown a high correlation with VO2max (53).  All methods of 
measuring physical fitness have, however, limitations because physical fitness is an integrated 
measure of aerobic performance dependent upon multi-organ function. Physical fitness also 
reflects psychological drive to exercise until exhaustion besides physiological ability. The 
mode of exercise may also play a role in the ability to reach the individuals maximal aerobic 
capacity (121).  
HDL and Physical Fitness 
One should expect that the association between baseline HDL and the outcome would be 
influenced if subsequent changes in physical fitness had the ability to improve HDL quality. 
The results must, however, be interpreted with caution since we did not have follow-up 
measures of HDL and therefore cannot study changes in HDL levels during the same time 
span. We have investigated the influence of the cross sectional gradient of physical fitness, 
and the natural course of changes in physical fitness on the predictive ability of HDL. This 
may influence HDL differently from exercise intervention as HDL response to exercise may 
vary with the kind of exercise, intensity, duration and acute effects of exercise may also differ 
from chronic effects of repeated exercise (40, 92, 94, 122). Our findings should therefore not 
be interpreted to mean that changes in HDL properties are impossible by physical exercise 
intervention which may affect lipid metabolism differently than spontaneous changes in 
physical fitness do. As previously mentioned, the response of blood lipids to physical exercise 
and increased physical fitness is complex and also vary with age, gender and several other 
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characteristics (94). In addition, it is estimated that as much as 25-40% of the level of physical 
fitness may be genetically determined. The ability to respond to exercise with increase in 
physical fitness also appears to vary significantly between individuals (123). We have shown 
that HDL seems to be independent of physical fitness when predicting CVD risk.  
Exercise blood pressure and Physical Fitness 
Adjustments for physical fitness and temporal changes in physical fitness weakened the 
association between changes in exercise blood pressure and disease risk in the present study. 
The changes in hazard ratios between the highest and the lowest quartile of exercise blood 
pressure imposed by adjusting for physical fitness and its changes were numerically in the 
similar range for all the endpoints, but there was no longer a significant association between 
exercise blood pressure and CVD- or all-cause death. Exercise blood pressure moderate 
workload and physical fitness are to some degree inversely correlated, and may represent 
different expressions of the same underlying physiological mechanisms. Adjusting for 
physical fitness and its changes might therefore be unnecessary, potentially underestimating 
the prognostic information of exercise blood pressure. On the contrary, it is possible that high 
levels of physical fitness and increase in physical fitness protect against the hazard associated 
with an increase in exercise blood pressure. This possible protective effect may be mediated 
through improving cardiovascular risk factors not accounted for in the present study, e.g. 
changes in endothelial properties (124, 125).  
Physical fitness, triglycerides and diabetes   
Adjustments for physical fitness had modest impact on the association between FTG and  
future diabetes risk. Directed acyclic graphs method (DAG) was used to determine the 
primary adjustment model for survival model, and body mass index (BMI) was not necessary 
to estimate the risk of type 2 diabetes. However, when adding BMI in a supplementary model, 
the adjustment for physical fitness had similar impact on the association compared with the 
primary adjustment model. Our results demonstrate an interaction between FTG and physical 
fitness in the type 2 diabetes risk prediction, being slightly stronger in unfit men compared to 
fit men. Changes in physical fitness over seven years did, however not modify the association 
between FTG changes type 2 diabetes risk.  
 Development of  type 2 diabetes is caused by a complex interplay of genetic factors 
and lifestyle. Physical fitness could therefore modify the association between the risk of type 
2 diabetes and FTG involving  several possible mechanisms. To derive these mechanisms is 
challenging by the use of observational studies and we have attemted to suggest explanations 
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with existing data. First, FTG and physical fitness are both independent predictors of type 2 
diabetes. Although inversely correlated, the two predictors convey somewhat different 
information about underlying genetic- and lifestyle factors. All these factors are not accounted 
for in our measurements and adjustments, and the modifying effect on the risk association 
might be explained by inclusion of more adjustment variables, weakening the independent 
impact of one predictor. This may also be the main reason why we found FTG to be a stronger 
predictor of diabetes in unfit than fit men.  
 Given the modifying effect of physical fitness on the association between point 
measures of FTG and diabetes risk, it was somewhat surprising that adjustments for physical 
fitness and seven-year changes in physical fitness had no impact on the association between 
seven-year changes in FTG levels and diabetes risk. Physical fitness had, however, a modest 
impact only on the FTG-diabetes association. Furthermore, physical fitness measured at 
survey 1 was not significantly different between categories of seven year change in FTG 
levels. Additionally, the change in physical fitness was numerically relatively small in all 
categories of FTG-change, -0.08 (kJ kg-1) to -0.17 (kJ kg-1) among men with a reduction in 
FTG of more than 25% and an increase of more than 25% respectively. Since we studied the 
FTG changes among a subset of 1387 men who were apparently healthy and free from 
diabetes at the second survey, it is unlikely that the levels of physical fitness and its changes 
are representative for men of the same age in the general population. This may have 
influenced the results.  
Physical fitness or self reported physical activity?  
Despite significant differences in physical fitness, we did not find any differences in self 
reported physical activity when comparing the baseline HDL quartiles in our study. Physical 
fitness was a significant, independent predictor of CHD and death whereas self-reported 
physical activity was not.  
 In line with previous reports, we found that physical fitness showed a stronger inverse 
association with diabetes risk than self reported physical activity did. Consequently, our 
findings are in line with previous knowledge that self reported physical activity and measured 
physical fitness are not necessarily highly correlated and that physical fitness should generally 
be preferred as a predictor of CVD and diabetes (48, 126). Self-reported physical activity is a 
subjective measure, and is burdened with recall bias and measurement errors. The level of 
physical fitness may also reveal physiological information not related to physical activity per 
se since an important proportion of physical fitness probably is genetically determined (127). 
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 Exercise testing to determine physical fitness is, however costly and may not always 
be feasible for routine use. Estimates of physical fitness, not measured in exercise testing, 
might therefore seem attractive and may provide valuable prognostic information (128). 
However, further studies are needed to show the value of self-reported physical fitness when 
predicting CVD and type 2 diabetes.    
The value of repeated testing  
We found that both seven-years changes in exercise blood pressure was a significant predictor 
of CHD, CHD death and CVD death while a decrease in FTG was a significant predictor of 
reduced diabetes-risk. In both studies, the association was adjusted for the baseline level of 
the predictor studied. Given the significant prognostic impact of changes in some predictors 
of diabetes and CVD, repeated testing seems important in risk estimation, and should thus 
probably be considered in epidemiological studies when possible. Causality cannot be proven 
from epidemiological studies alone. One might, however, argue that associated changes in 
levels of a predictor and risk of outcome may indicate a higher likelihood of causality as 
compared to traditional point measure-outcome associations.  
 Repeated measurements in epidemiological studies to assess the predictive impact of 
spontaneous or life-style induced changes on outcome give important knowledge. This may 
be useful when designing intervention studies and interpreting results from them. This kind of 
epidemiological knowledge may be particularly important when an intervention fails to 
improve the disease risk despite improving a variable. An example of this was that the use of 
torcetrapib succeeded in raising HDL levels but failed to decrease CVD risk (129). In such 
cases, robust epidemiological evidence about associated temporal changes in risk marker and 
changes in outcome may help both in interpretation of results and also possibly in planning of 
further research on modifying the risk marker.    
Is there a unifying link between HDL, exercise SBP and serum triglycerides?  
Low HDL levels and high levels of serum triglycerides are associated with insulin resistance 
(130). Reduced insulin sensitivity has been shown to be associated with increased exercise 
SBP, poor physical fitness and impaired vasodilatation in apparently healthy young people 
(106, 131).  As presented in this thesis, both low HDL levels and increased exercise SBP are 
associated with increased risk of CHD and death from CHD and CVD. Elevated FTG levels 
predict increased risk of diabetes, while temporal reductions in FTG levels predict reduced 
risk of diabetes. Fasting serum triglycerides also predict increased risk of CHD and CVD in 
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the Oslo Ischemia Study cohort, but the association did not reach statistical significance when 
adjusted for other CVD risk factors (unpublished data). The common denominator between 
the predictor presented in this thesis appears to be insulin sensitivity.  
Strengths and limitations  
Strengths 
The cohort has been followed prospectively, all data sets are virtually complete and the 
findings refer to an apparently healthy population of middle-aged men followed for up to 35 
years. All participants were examined under standardized conditions by the same physician 
(JE) at both Survey 1 and 2, and JE also closely supervised subsequent surveys.  We have no 
work-up bias, and all event data are based on cause-specific death records and complete 
hospital records. Furthermore, all diagnoses of non-fatal events have been verified by 
physicians and cross-checked by two of the study investigators, and none are self-reported. 
Since the study group has not interfered with patient care, bias is minimized. None of the 
predictors investigated in our studies have been systematically or intentionally modified in 
any way neither before baseline, nor during the time span during which changes in predictors 
have been measured. Changes in predictors studied are therefore likely to reflect a natural 
course depending on lifestyle and age rather than treatment interventions.  
Limitations  
 Our cohort consists of middle-aged Caucasian men who were healthy and employed at 
baseline. Our findings therefore, cannot be generalized to individuals of differing ethnicity, 
age, gender or individuals with morbidity.  
 The men included in the Oslo Ischemia Study were relatively lean with a BMI of 24.6 
kg/m2, and only 335 (16.6%) men out of the 2014 had a BMI of more than 27 kg/m2 whereas 
it was estimated that 27% of Norwegian men 16 to 44 years and 38% of men 45 to 79 years of 
age had a BMI of more than 27 kg/m2 in 2012. Further, 882 (43.8) men in the cohort were 
smokers at inclusion. The proportion of daily smokers in the Norwegian population has been 
more than halved since the study was initiated (132). These changes are only examples of 
several changes in lifestyle and demographics since initiation of the Oslo Ischemia Study 
which requires caution if projecting these associations into the future.   
 The original aim of the Oslo Ischemia Study was to assess the prevalence and 
incidence of significant coronary artery disease within a cohort of apparently healthy middle-
aged men. Initially, the follow-up was planned to be 5 years. All studies presented in this 
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thesis are based on follow-up extended up to 35 years and hypotheses developed more than 
three decades after inclusion of participants in cohort. It is difficult to assess how this might 
have influenced our findings. This should be kept in mind when interpreting results since the 
likelihood of finding spurious associations might increase with this method (133). On the 
contrary, all our hypotheses were specified before analysing any data, and all were 
biologically plausible.   
 Men who got various diseases between the surveys used in our studies were excluded 
when analyzing the prognostic impact of changes between those surveys. This was done 
deliberately because we wanted to study the prognostic impact among apparently healthy men 
and not among a mixed group of healthy and not healthy men. By this method, one will end 
up with an increasingly selected group of healthy individuals; and thereby probably increase 
the likelihood of introducing type II statistical errors. This concern was investigated with 
additional analyses of triglyceride changes excluding only men who got diabetes between 
Survey 1 and 2 while those who got other disease e.g. CVD were included. We found no 
important impact on results by performing this sensitivity analysis. We therefore believe that 
the selection of men who stayed healthy until Survey 2 did not introduce important selection 
bias impacting into our study of the triglyceride changes and diabetes risk, but similar 
analyzes were not performed in the other studies presented in this thesis.   
 Regression to the mean  
All repeated measurements of biological variables may be influenced by the "regression to the 
mean" phenomenon. This phenomenon occurs because of the variability of both the 
measurement method and inherent physiological variation. Values that are outliers, or extreme 
at its first measurement will have a greater likelihood of being closer to the mean on a 
repeated measurement (134). The magnitude of regression to the mean may be estimated by 
statistical methods, and may also be reduced by serial measurements and using the average of 
those (134). In clinical intervention studies, one of the important effects of randomization is to 
reduce the impact of regression to the mean. In our studies of spontaneous changes in 
predictors, none of the above methods have been applied in order to reduce regression to the 
mean. The numeric values of the changes are therefore likely to have been higher than the real 
biological change, but will thereby also probably underestimate the strength of the 
associations between true changes and outcome.  
 Furthermore, the levels of many biological variables show a considerably inherent 
seasonal-, or circadian variation (83). Some variables may also vary during the week, 
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probably as a cause of changes in mental and physiological stress, eating and alcohol intake. 
Measurements should therefore preferably be repeated the same time of the day, same 
weekday and same time of the year each time when studying changes. Our measurements 
were not standardized this way at repeated surveys, but all measurements were performed in 
the morning in otherwise standardized conditions. When assessing changes of fasting serum 
triglycerides in prediction of diabetes, we performed additional adjustments for the time at 
which measurements were performed, and this had no impact on the results.    
Endpoints  
The diagnosis of angina pectoris was not confined to men with objective evidence of 
myocardial ischemia, and misdiagnosis cannot be ruled out. This potential limitation has been 
thoroughly discussed in Paper 1. After assessment of later CHD events among men diagnosed 
with angina pectoris compared to men without the diagnosis, we found that our diagnostic 
criteria appear to be sufficiently precise.     
 As discussed in Paper 3, our diagnosis of diabetes was based on the WHO 85 criteria 
to enable us to keep uniform criteria throughout the whole observation period. Available 
diagnostic information was not nearly sufficient to be able to apply modern diagnostic criteria 
retrospectively. It is difficult to estimate how modern diagnostic criteria would have 
influenced our results with respect to the FTG-diabetes association.  
 We believe that all other endpoints have high diagnostic validity compared to other 
long-term cohort studies as discussed in Strengths. Although we always have used the same 
diagnostic criteria for e.g. myocardial infarction in Oslo Ischemia Study, diagnostic criteria 
for myocardial infarction have changed since the seventies. We can only speculate have 
modern criteria would have influenced our results (135). We are however, confident that our 
definitions were robust in diagnosing myocardial infarctions, and that our results are more 
likely to underestimate than to overestimate risks. Further, the incidence, prevalence and 
treatment of CHD have changed since the Oslo Ischemia Study was initiated (1-4). All these 
changes make generalization of our exact results into today's epidemiology somewhat 
difficult. Even though, we believe that the above mentioned limitations are unlikely to affect 
individuals with different levels of predictors in a much skewed manner. We therefore believe 
that our results to a large extent are still valid for apparently healthy middle-aged men of 
Caucasian origin.    
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Alcohol  
The participants responded to a questionnaire at inclusion in the Oslo Ischemia Study about 
drinking habits the last days prior to examination. These answers were considered to reveal 
part of their propensity to use alcohol. We have, however no detailed data with respect to 
amounts of alcohol consumed and no systematic information on alcohol consumption during 
follow-up. Lack of detailed data on alcohol consumption must be considered as an important 
limitation in our studies as alcohol intake may have significant impact on the levels of HDL, 
TG and SBP besides several other effects on the cardiovascular system (136). On the 
contrary, all participants in Oslo Ischemia Study were fully employed at inclusion and none 
reported alcohol abuse. This should support the notion that the average use of alcohol was 
within normal limits.  
Clinical perspective  
Our results are in line with existing evidence that HDL levels and physical fitness are 
associated to some extent. We found, however that HDL`s predictive ability on CHD and 
CVD remains similar at all levels of physical fitness among healthy middle-aged men. This 
finding supports that HDL level may be used for risk estimation without considering the level 
of physical fitness. This is in accordance with what has been done in the electronic version of 
the SCORE system as mentioned in Introduction. Further, our results indicate that HDL levels 
should be taken into account when estimating risk of CHD and CVD regardless of the level of 
physical fitness. Further research is needed to assess if our findings are valid for women, all 
age groups and people of other ethnicity.  
 Based on a previous publication from the Oslo Ischemia Study  and some other studies 
that have shown prognostic impact of exercise blood pressure on CVD, the 2013 ESH/ESC 
hypertension guidelines have been changed and recommend ambulatory blood pressure 
measurement in the setting of normal resting blood pressure and an exaggerated blood 
pressure response to exercise (20, 73, 100).  
 The association we found between temporal changes in exercise blood pressure and 
future risk of CHD and death support previous evidence of a strong association between blood 
pressure measured at low- to moderate exercise and CVD risk. If confirmed in other studies, 
exercise blood pressure should be further investigated as a potential target of risk 
modification.  
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 Future research should also compare the cost-effectiveness and predictive ability of 
ambulatory blood pressure and exercise blood pressure at low- to moderate workload both in 
CVD risk estimation and to reveal masked hypertension.   
 We found that high levels of physical fitness reduce the increased risk of diabetes only 
modestly. High levels of FTG should therefore not be neglected as a risk marker of future 
diabetes in fit individuals although the absolute risk of diabetes is lower than in unfit 
individuals. Significant reductions in FTG levels appear to be closely associated with 
significant and clinically important reduction in diabetes risk among healthy middle-aged 
men. If our findings are supported by future studies, methods of reducing FTG levels and their 
impact on diabetes risk should be investigated.  
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Conclusions  
 
1. High-density lipoprotein cholesterol is a strong predictor of long-term risk of coronary 
heart disease and death from coronary heart- and cardiovascular disease in apparently 
healthy middle aged men. Physical fitness at baseline and changes in physical fitness after 
8.6 years did not reduce the ability of HDL to predict CHD.                                                                          
 
2. An increase in exercise SBP at 100W over seven years is independently associated with 
significantly increased long-term risk of CHD, CHD death, CV death and all-cause death. 
These associations are, however to some degree attenuated by physical fitness and 
temporal change in physical fitness. Our findings also support that increased exercise SBP 
is a strong long term cardiovascular risk factor in healthy men.    
                                                                                                                                                
3. Fasting serum triglyceride levels are significant long-term predictors of diabetes among 
healthy middle-aged men and adjustments for physical fitness attenuates this association 
only modestly. Fasting serum triglycerides appear to be a stronger predictor of diabetes in 
men with poor physical fitness than in fit men. A reduction in fasting triglycerides over 
time is associated with reduced long-term risk of diabetes.   
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